Hologic, Inc. (NASDAQ:HOLX) – Analysts at Gabelli lifted their FY2018 earnings per share estimates for Hologic in a research report issued to clients and investors on Tuesday, Zacks Investment Research reports. Gabelli analyst S. Wojda now forecasts that the medical equipment provider will post earnings of $2.30 per share for the year, up from their prior estimate of $2.15. Gabelli also issued estimates for Hologic’s FY2019 earnings at $2.60 EPS, FY2020 earnings at $2.85 EPS and FY2021 earnings at $3.00 EPS.
Other equities analysts have also issued research reports about the company. Jefferies Group restated a “buy” rating and set a $44.00 price objective (down previously from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. Stifel Nicolaus restated a “buy” rating and set a $45.00 price objective (down previously from $48.00) on shares of Hologic in a research note on Monday, October 9th. Cowen upgraded Hologic to a “buy” rating and set a $52.00 price target on the stock in a research note on Wednesday, December 20th. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price target (up previously from $46.00) on shares of Hologic in a research note on Tuesday, December 5th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $48.00 price target on shares of Hologic in a research note on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $48.79.
Hologic (NASDAQ:HOLX) opened at $42.04 on Thursday. Hologic has a 52 week low of $35.76 and a 52 week high of $46.80. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79. The company has a market capitalization of $11,440.00, a price-to-earnings ratio of 15.92, a price-to-earnings-growth ratio of 2.00 and a beta of 0.77.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million for the quarter, compared to analyst estimates of $792.54 million. During the same quarter last year, the company earned $0.52 EPS. The company’s revenue was up 10.5% on a year-over-year basis.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. Parnassus Investments CA acquired a new stake in shares of Hologic during the 3rd quarter valued at $277,062,000. Capital World Investors acquired a new position in Hologic during the 2nd quarter worth about $312,441,000. HealthCor Management L.P. acquired a new position in Hologic during the 2nd quarter worth about $76,604,000. Vanguard Group Inc. lifted its holdings in Hologic by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after buying an additional 1,200,825 shares during the period. Finally, Koch Industries Inc. lifted its holdings in Hologic by 15,554.1% during the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after buying an additional 1,142,138 shares during the period. 97.10% of the stock is currently owned by institutional investors.
In related news, VP Karleen Marie Oberton sold 1,256 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $39.29, for a total transaction of $49,348.24. Following the sale, the vice president now owns 9,406 shares of the company’s stock, valued at approximately $369,561.74. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $40.50, for a total value of $375,921.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,099 shares of company stock worth $487,223. Corporate insiders own 0.79% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “FY2018 Earnings Forecast for Hologic, Inc. Issued By Gabelli (NASDAQ:HOLX)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/03/gabelli-weighs-in-on-hologic-inc-s-fy2018-earnings-holx.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Get a free copy of the Zacks research report on Hologic (HOLX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.